| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2008.18.6916 |
| P698 | PubMed publication ID | 19124805 |
| P50 | author | Norbert Ifrah | Q56549745 |
| Yves Chalandon | Q60732144 | ||
| P2093 | author name string | Xavier Thomas | |
| Elizabeth Macintyre | |||
| Marie-Christine Béné | |||
| Eric Delabesse | |||
| Emmanuel Raffoux | |||
| Hervé Dombret | |||
| Jean-Paul Vernant | |||
| André Delannoy | |||
| Françoise Huguet | |||
| Marina Lafage-Pochitaloff | |||
| Patrice Chevallier | |||
| Thibaut Leguay | |||
| Véronique Lhéritier | |||
| Kheira Beldjord | |||
| Agnes Buzyn | |||
| Agnès Chassevent | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| Philadelphia chromosome | Q1129111 | ||
| lymphoblastic leukemia | Q18553852 | ||
| P304 | page(s) | 911-918 | |
| P577 | publication date | 2009-01-05 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study | |
| P478 | volume | 27 |
| Q38871220 | A case of me: clinical cancer sequencing and the future of precision medicine |
| Q37437708 | A childhood chemotherapy protocol improves overall survival among adults with T-lymphoblastic lymphoma |
| Q48763487 | A decision analysis of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission who have an HLA-matched sibling donor |
| Q40473999 | A phase 1/2 trial of lenalidomide and dexamethasone in adult patients with refractory/relapsed acute lymphoblastic leukemia. |
| Q49412789 | A retrospective comparison of Escherichia coli and polyethylene glycol-conjugated asparaginase for the treatment of adolescents and adults with newly diagnosed acute lymphoblastic leukemia |
| Q45309842 | Absence of terminal deoxynucleotidyl transferase expression identifies a subset of high-risk adult T-lymphoblastic leukemia/lymphoma |
| Q33437766 | Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre-leukaemic clone resulting in T2-ALL and AML-M0 |
| Q92311313 | Acute Lymphoblastic Leukemia in Routine Practice: A Turkish Multicenter Study |
| Q91565663 | Acute lymphoblastic leukaemia |
| Q39192991 | Acute lymphoblastic leukemia in adolescents and young adults |
| Q38095113 | Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates |
| Q37575938 | Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study |
| Q39406969 | Acute lymphoblastic leukemia: a comprehensive review and 2017 update |
| Q40532933 | Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden |
| Q37990381 | Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis |
| Q39396416 | Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study |
| Q93013059 | Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation |
| Q43833498 | Adult acute lymphoblastic leukaemia in Denmark. A national population-based retrospective study on acute lymphoblastic leukaemia in Denmark 1998-2008. |
| Q37681450 | Adult acute lymphoblastic leukemia: concepts and strategies |
| Q39459190 | Advances in adult acute lymphoblastic leukemia therapy |
| Q33632278 | Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia |
| Q38087853 | Allogeneic hematopoietic cell transplantation from alternative sources for adult Philadelphia chromosome-negative ALL: what should we choose when no HLA-matched related donor is available? |
| Q34145155 | Allogeneic hematopoietic cell transplantation: the state of the art |
| Q37919867 | Allogeneic stem cell transplant for adult Philadelphia chromosome-negative acute lymphoblastic leukemia |
| Q40765997 | Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission |
| Q30577948 | Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis |
| Q37237899 | An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study |
| Q45971930 | An effective reinduction regimen for first relapse of adult acute lymphoblastic leukemia. |
| Q42634946 | Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen |
| Q27013710 | Antigen-based immunotherapy for the treatment of acute lymphoblastic leukemia: the emerging role of blinatumomab |
| Q40243523 | Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA. |
| Q38696311 | Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase |
| Q34550540 | Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). |
| Q26784116 | Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase |
| Q86351516 | Blinatumomab: a new era of treatment for adult ALL? |
| Q54660373 | Bone Marrow Necrosis in Newly Diagnosed Acute Leukemia: Two Case Reports and Review of the Literature. |
| Q48882156 | Bortezomib interferes with adhesion of B cell precursor acute lymphoblastic leukemia cells through SPARC up-regulation in human bone marrow mesenchymal stromal/stem cells |
| Q49652236 | CD20 positivity and white blood cell count predict treatment outcomes in Philadelphia chromosome-negative acute lymphoblastic leukemia patients ineligible for pediatric-inspired chemotherapy |
| Q34300704 | CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis |
| Q82340377 | CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry |
| Q36552098 | Cellular therapies in acute lymphoblastic leukemia |
| Q40691962 | Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience |
| Q39401736 | Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice |
| Q46424183 | Clinical significance of minimal residual disease in young adults with standard-risk/Ph-negative precursor B-acute lymphoblastic leukemia: results of prospective study |
| Q92214898 | Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study |
| Q37273171 | Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts |
| Q52852382 | Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia. |
| Q94496786 | Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT |
| Q40179856 | Comparison of survival of adolescents and young adults with hematologic malignancies in Osaka, Japan |
| Q39366299 | Continuing challenges and current issues in acute lymphoblastic leukemia. |
| Q47706549 | Current challenges and opportunities in treating adult patients with Philadelphia-negative acute lymphoblastic leukaemia. |
| Q33875893 | Current status and future directions of clinical research and practice in adult acute lymphoblastic leukemia patients in Korea |
| Q41476785 | Deferring allogeneic transplantation for adult acute lymphoblastic leukemia: is there a second chance? |
| Q90435071 | Differential efficacy of empirical antibiotic therapy for febrile neutropenia in adolescent/young adult (AYA) and child patients |
| Q34455093 | Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. |
| Q64040545 | Double-delayed intensification paediatric protocol without radiotherapy is an efficient treatment in adult lymphoblastic lymphoma |
| Q41724569 | Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia |
| Q48136104 | Effectiveness of modified hyper-CVAD chemotherapy regimen in the treatment of adult acute lymphoblastic leukemia: a retrospective experience. |
| Q53780635 | Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia. |
| Q49818206 | Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia. |
| Q53239133 | Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003. |
| Q38172586 | Emerging drugs for acute lymphocytic leukemia |
| Q64897905 | Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia. |
| Q59296762 | Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocol |
| Q40754724 | Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen |
| Q42141317 | Frequency of p190 and p210 BCR-ABL rearrangements and survival in Brazilian adult patients with acute lymphoblastic leukemia |
| Q37490450 | Hepatomegaly and fever at the time of neutrophil recovery revealing L-asparaginase toxicity in the treatment of acute lymphoblastic leukemia |
| Q36216252 | High curability via intensive reinduction chemotherapy and stem cell transplantation in young adults with relapsed acute lymphoblastic leukemia in Sweden 2003-2007. |
| Q45121577 | High hyperdiploidy among adolescents and adults with acute lymphoblastic leukaemia (ALL): cytogenetic features, clinical characteristics and outcome. |
| Q40044204 | High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: A phase III study by JALSG. |
| Q28087589 | How I treat acute lymphoblastic leukemia in older adolescents and young adults |
| Q91011081 | Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL |
| Q50315932 | Immunophenotypic Characteristics of T-Acute Lymphoblastic Leukemia in Omani Patients: A Correlation with Demographic Factors |
| Q38787405 | Immunotherapy approaches to treat adult acute lymphoblastic leukemia |
| Q41472241 | Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival |
| Q51794155 | Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic leukemia. |
| Q93184559 | Indications for allogeneic hematopoietic cell transplantation for adults with Philadelphia-chromosome negative acute lymphoblastic leukemia in first complete remission: all about MRD? |
| Q38984055 | Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia. |
| Q55205941 | Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia. |
| Q40295439 | Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study |
| Q44232638 | Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40. |
| Q50561292 | Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 study |
| Q83494408 | Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVON |
| Q83180903 | Intrathecal liposomal cytarabine (lipoCIT) administration in patients with leukemic or lymphomatous meningitis: efficacy and long-term safety in a single institution |
| Q55554910 | L-asparaginase for adult CD20 positive B-cell precursor acute lymphoblastic leukemia. |
| Q26738640 | L-asparaginase in the treatment of patients with acute lymphoblastic leukemia |
| Q90127243 | Levocarnitine does not impair chemotherapy cytotoxicity against acute lymphoblastic leukemia |
| Q35178966 | Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. |
| Q90182571 | Low level CpG island promoter methylation predicts a poor outcome in adult T-cell acute lymphoblastic leukemia |
| Q51042899 | Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients. |
| Q44297298 | Lymphatic neoplasias in young patients |
| Q35820095 | Management and treatment of relapsed or refractory Ph(-) B-precursor ALL: a web-based, double-blind survey of EU clinicians |
| Q37766527 | Management of adult patients with acute lymphoblastic leukemia in first complete remission: systematic review and meta-analysis |
| Q34454611 | Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group. |
| Q52915505 | Meta-analysis and meta-regression analysis to compare the outcomes of chemotherapy for T- and B-lineage acute lymphoblastic leukemia (ALL): the use of dexamethasone, L-asparaginase, and/or methotrexate may improve the outcome of T-lineage ALL. |
| Q44670719 | Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study. |
| Q92860019 | Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances |
| Q38312596 | Modern immunotherapy of adult B-lineage acute lymphoblastic leukemia with monoclonal antibodies and chimeric antigen receptor modified T cells |
| Q40817792 | Modern therapy of young and adult Ph-ALL. |
| Q36616666 | Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study) |
| Q27022540 | Monoclonal antibodies in acute lymphoblastic leukemia |
| Q37613872 | Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia |
| Q36339717 | Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia |
| Q91898942 | Multiple Severe Toxicities of L-Asparaginase and Their Innovative Management during Induction Therapy of Acute Lymphoblastic Leukemia in an Adult Patient |
| Q93120938 | New biomarkers and therapeutic strategies in acute lymphoblastic leukemias: Recent advances |
| Q39307476 | New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? |
| Q38428357 | New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia |
| Q26829775 | Novel agents and biomarkers for acute lymphoid leukemia |
| Q38094099 | Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies |
| Q37931235 | Optimal pharmacotherapeutic management of acute lymphoblastic leukaemia in the elderly |
| Q37883008 | Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults |
| Q38434311 | Optimizing treatment in paediatric rheumatology--lessons from oncology |
| Q34610024 | Outcome of Adolescents with Acute Lymphoblastic Leukemia Treated by Pediatrics versus Adults Protocols |
| Q82331227 | Outcome of adults with acute lymphoblastic leukemia treated with a pediatric-inspired therapy: a single institution experience |
| Q28543517 | Outcome of central nervous system relapses in childhood acute lymphoblastic leukaemia--prospective open cohort analyses of the ALLR3 trial |
| Q34300854 | Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial |
| Q48311791 | Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis |
| Q45934886 | PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study. |
| Q37970679 | Pathogenetic, Clinical, and Prognostic Features of Adult t(4;11)(q21;q23)/MLL-AF4 Positive B-Cell Acute Lymphoblastic Leukemia |
| Q48515641 | Patients over 40 years old with precursor T-cell lymphoblastic lymphoma have different prognostic factors comparing to the youngers |
| Q88400653 | Patterns of care and outcomes in adolescent and young adult acute lymphoblastic leukemia: a population-based study |
| Q49951910 | Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review. |
| Q36609579 | Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission |
| Q38200565 | Pediatric-like therapy for adults with ALL. |
| Q37719558 | Peg-asparaginase for acute lymphoblastic leukemia |
| Q31118945 | Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial |
| Q37851951 | Pharmacotherapeutic advances in the treatment of acute lymphoblastic leukaemia in adults |
| Q38392656 | Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia |
| Q38282458 | Philadelphia chromosome-negative acute lymphoblastic leukemia: therapies under development |
| Q37810967 | Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options |
| Q33410062 | Pneumonia during remission induction chemotherapy in patients with acute leukemia |
| Q82909719 | Posterior reversible encephalopathy syndrome in an adult patient with acute lymphoblastic leukemia after remission induction chemotherapy |
| Q26764903 | Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia |
| Q89768692 | Practical guidance for the management of acute lymphoblastic leukemia in the adolescent and young adult population |
| Q47564576 | Pre-Transplant Consolidation is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation |
| Q37914185 | Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel |
| Q49838769 | Prognostic impact of CD200 and CD56 expression in adult acute lymphoblastic leukemia patients. |
| Q92667732 | Prognostic impact of cytogenetic abnormalities in adult patients with Philadelphia chromosome-negative ALL who underwent an allogeneic transplant |
| Q42765021 | Prognostic relevance of CD20 in adult B-cell precursor acute lymphoblastic leukemia |
| Q49989324 | Progress in adult ALL: incorporation of new agents to frontline treatment. |
| Q33886231 | Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia. |
| Q35669875 | Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia |
| Q89286746 | Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic Leukemia |
| Q28078076 | Recent advances and novel treatment paradigms in acute lymphocytic leukemia |
| Q92276422 | Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia |
| Q36579091 | Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups |
| Q44657508 | Redefining transplant in acute leukemia |
| Q90215009 | Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia; Current Evidence, and Improving Outcomes Going Forward |
| Q86297200 | Resistance revealed in acute lymphoblastic leukemia |
| Q36036328 | Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial |
| Q37695157 | Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults |
| Q47196522 | Rituximab in the management of acute lymphoblastic leukemia |
| Q34532041 | Role of allogeneic hematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukemia. |
| Q39194553 | Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia |
| Q44783681 | Satisfactory outcome after intensive chemotherapy with pragmatic use of minimal residual disease (MRD) monitoring in older patients with Philadelphia-negative B cell precursor acute lymphoblastic leukaemia: a Swedish registry-based study. |
| Q37662200 | Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. |
| Q50960101 | Survival disparities by age and country of diagnosis for patients with acute leukemia |
| Q91915097 | Survival in adult acute lymphoblastic leukaemia (ALL): A report from the Swedish ALL Registry |
| Q39176628 | Survival of adolescents with cancer treated at pediatric versus adult oncology treatment centers in France |
| Q90703622 | T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol |
| Q38169656 | T-cell adoptive immunotherapy for acute lymphoblastic leukemia |
| Q90413960 | The Physiopathology of T- Cell Acute Lymphoblastic Leukemia: Focus on Molecular Aspects |
| Q37273178 | The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest |
| Q40104215 | The prognostic value of glucocorticoid receptors for adult acute lymphoblastic leukemia |
| Q37844312 | The role of allogeneic stem cell transplantation for adult acute lymphoblastic leukemia |
| Q46639944 | The superiority of allogeneic hematopoietic stem cell transplantation from unrelated donor over chemotherapy for adult patients with high-risk acute lymphoblastic leukemia in first remission |
| Q38096307 | The treatment of adolescents and young adults with acute lymphoblastic leukemia |
| Q39387524 | The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance |
| Q42943448 | Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia |
| Q38134399 | Therapeutic approaches to haematological malignancies in adolescents and young adults |
| Q37605864 | Therapy of Philadelphia chromosome-negative acute lymphoblastic leukemia in adults: new paradigms |
| Q57020375 | Toward the potential cure of leukemias in the next decade |
| Q91240560 | Traitement par CAR-T des leucémies aiguës de l'adulte |
| Q30243925 | Treating adults with acute lymphocytic leukemia: new pharmacotherapy options |
| Q54507760 | Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia with imatinib combined with a paediatric-based protocol. |
| Q39206217 | Treatment of Young Adults with Acute Lymphoblastic Leukemia |
| Q37899785 | Treatment of acute lymphoblastic leukemia in adolescents and young adults |
| Q33920153 | Treatment of adolescent and young adults with acute lymphoblastic leukemia |
| Q45395583 | Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol |
| Q35755000 | Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy |
| Q90606756 | Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens |
| Q102058897 | Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18-65 years: NILG ALL 10/07 |
| Q38953608 | Who Should Receive a Transplant for Acute Lymphoblastic Leukaemia? |
| Q88665500 | [Chinese guidelines for diagnosis and treatment of acute lymphoblastic leukemia(2016)] |
| Q87195903 | [Treatment of Ph-adult acute lymphoblastic leukemia patients with Tongji-96 regimen] |
| Q89255976 | [Treatment of relapsed and refractory acute lymphocytic leukemia by modified CAG regimen] |
Search more.